Seminars in Fetal & Neonatal Medicine
Volume 14, Issue 4 , Pages 218-221 , August 2009

Parvovirus B19 infection

References 

  1. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988;25:151–153
  2. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1(7898):72–73
  3. Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science. 1986;233(4766):883–886
  4. Cotmore SF, Tattersall P. Characterization and molecular cloning of a human parvovirus genome. Science. 1984;226(4679):1161–1165
  5. Gallinella G, Venturoli S, Manaresi E, Musiani M, Zerbini M. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol. 2003;28:1–13
  6. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002;76:9124–9134
  7. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:8230–8236
  8. Simmonds P, Douglas J, Bestetti G, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol. 2008;89(Pt 9):2299–2302
  9. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–12896
  10. Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316:183–186
  11. Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant. 2001;5:320–330
  12. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75:97–102
  13. Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986;24:522–526
  14. Schwarz TF, Gurtler LG, Zoulek G, Deinhardt F, Roggendorf M. Seroprevalence of human parvovirus B19 infection in Sao Tome and Principe, Malawi and Mascarene Islands. Zentralbl Bakteriol. 1989;271:231–236
  15. Tolfvenstam T, Enbom M, Ghebrekidan H, et al. Seroprevalence of viral childhood infections in Eritrea. J Clin Virol. 2000;16:49–54
  16. de Freitas RB, Wong D, Boswell F, et al. Prevalence of human parvovirus (B19) and rubella virus infections in urban and remote rural areas in northern Brazil. J Med Virol. 1990;32:203–208
  17. Kleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007;47:1756–1764
  18. Thomas I, Di Giambattista M, Gerard C, et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang. 2003;84:300–307
  19. Tsujimura M, Matsushita K, Shiraki H, et al. Human parvovirus B19 infection in blood donors. Vox Sang. 1995;69:206–212
  20. Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol. 1995;91:1017–1018
  21. Lindblom A, Heyman M, Gustafsson I, et al. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis. 2008;46:528–536
  22. Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol. 1998;31:66–72
  23. Heegaard ED, Taaning EB. Parvovirus B19 and parvovirus V9 are not associated with Henoch–Schönlein purpura in children. Pediatr Infect Dis J. 2002;21:31–34
  24. Lundqvist A, Tolfvenstam T, Brytting M, et al. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis. 1999;31:119–122
  25. Anderson MJ, Cohen BJ. Human parvovirus B19 infections in United Kingdom 1984–86. Lancet. 1987;1(8535):738–739
  26. Gilbert NL, Gyorkos TW, Beliveau C, et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol Infect. 2005;133:299–304
  27. Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J. 1987;6:711–718
  28. Anderson LJ, Gillespie SM, Torok TJ, et al. Risk of infection following exposures to human parvovirus B19. Behring Inst Mitt. 1990;85:60–63
  29. Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. J Am Med Assoc. 1990;263:2061–2065
  30. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149:1153–1156
  31. Yaegashi N, Niinuma T, Chisaka H, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect. 1998;37:28–35
  32. Kerr JR, O'Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci. 1994;163:65–67
  33. Kinney JS, Anderson LJ, Farrar J, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis. 1988;157:663–667
  34. Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413–420
  35. Beigi RH, Wiesenfeld HC, Landers DV, Simhan HN. High rate of severe fetal outcomes associated with maternal parvovirus b19 infection in pregnancy. Infect Dis Obstet Gynecol. 2008;2008:524601
  36. Jensen IP, Thorsen P, Jeune B, Moller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. Br J Obstet Gynaecol. 2000;107:637–643
  37. Guidozzi F, Ballot D, Rothberg AD. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome. J Reprod Med. 1994;39:36–38
  38. Anonymous . Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. Br Med J. 1990;300(6733):1166–1170
  39. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984;2(8410):1033–1034
  40. Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol. 1996;174(1 Pt 1):37–42
  41. Garcia AG, Pegado CS, Cubel Rde C, et al. Feto-placentary pathology in human parvovirus B19 infection. Rev Inst Med Trop Sao Paulo. 1998;40:145–150
  42. Nunoue T, Kusuhara K, Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J. 2002;21:1133–1136
  43. Nyman M, Skjoldebrand-Sparre L, Broliden K. Non-hydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. J Perinat Med. 2005;33:176–178
  44. Sheikh AU, Ernest JM, O'Shea M. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol. 1992;167:337–341
  45. Riipinen A, Vaisanen E, Nuutila M, et al. Parvovirus B19 infection in fetal deaths. Clin Infect Dis. 2008;47:1519–1525
  46. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513–518
  47. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105:174–178
  48. Norbeck O, Papadogiannakis N, Petersson K, et al. Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin Infect Dis. 2002;35:1032–1038
  49. Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, et al. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. Br J Obstet Gynaecol. 2000;107:476–480
  50. Syridou G, Spanakis N, Konstantinidou A, et al. Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol. 2008;80:1776–1782
  51. Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet. 2001;357(9267):1494–1497
  52. Nyman M, Tolfvenstam T, Petersson K, et al. Detection of human parvovirus B19 infection in first-trimester fetal loss. Obstet Gynecol. 2002;99(5 Pt 1):795–798
  53. Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta. 1999;20:103–108
  54. Berry PJ, Gray ES, Porter HJ, Burton PA. Parvovirus infection of the human fetus and newborn. Semin Diagn Pathol. 1992;9:4–12
  55. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol. 1992;99:566–574
  56. Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol. 2001;8:288–292
  57. Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta. 2002;23:547–553
  58. von Kaisenberg CS, Bender G, Scheewe J, et al. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther. 2001;16:427–432
  59. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005;193:363–365
  60. Shneerson JM, Mortimer PP, Vandervelde EM. Febrile illness due to a parvovirus. Br Med J. 1980;280(6231):1580
  61. de Jong EP, de Haan TR, Kroes AC, et al. Parvovirus B19 infection in pregnancy. J Clin Virol. 2006;36:1–7
  62. Enders M, Schalasta G, Baisch C, et al. Human parvovirus B19 infection during pregnancy – value of modern molecular and serological diagnostics. J Clin Virol. 2006;35:400–406
  63. Dieck D, Schild RL, Hansmann M, Eis-Hubinger AM. Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn. 1999;19:1119–1123
  64. Skjoldebrand-Sparre L, Nyman M, Broliden K, Wahren B. All cases of intrauterine fetal death should be evaluated for parvovirus B19 viral deoxyribonucleic acid. Am J Obstet Gynecol. 1999;180(6 Pt 1):1595–1596
  65. Petersson K, Norbeck O, Westgren M, Broliden K. Detection of parvovirus B19, cytomegalovirus and enterovirus infections in cases of intrauterine fetal death. J Perinat Med. 2004;32:516–521
  66. Wolff K, Broliden K, Marsk A, et al. One stillborn and one severely hydropic twin due to parvovirus B19 infection; successful outcome of the surviving twin. Acta Obstet Gynecol Scand. 1999;78:828–830
  67. Knoll A, Louwen F, Kochanowski B, et al. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol. 2002;67:259–266
  68. Enders M, Weidner A, Rosenthal T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis. 2008;197:58–62
  69. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang. 1997;72:1–10
  70. Lindblom A, Isa A, Norbeck O, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis. 2005;41:1201–1203
  71. Lefrere JJ, Servant-Delmas A, Candotti D, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood. 2005;106:2890–2895
  72. Landolsi H, Yacoubi MT, Bouslama L, et al. Detection of the human Parvovirus B19 in nonimmune hydrops fetalis using immunohistochemistry and nested-PCR in formalin-fixed and paraffin-embedded placenta and fetal tissues Pathol Biol (Paris) in press, doi:10.1016/j.patbio.2007.11.001
  73. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187:675–678
  74. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. J Am Med Assoc. 1999;281:1099–1105
  75. Cosmi E, Mari G, Delle Chiaie L, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol. 2002;187:1290–1293
  76. Delle Chiaie L, Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001;18:232–236
  77. Bond PR, Caul EO, Usher J, et al. Intrauterine infection with human parvovirus. Lancet. 1986;1(8478):448–449
  78. Gray ES, Anand A, Brown T. Parvovirus infections in pregnancy. Lancet. 1986;1(8474):208
  79. Brennand JE, Cameron AD. Human parvovirus B19 in pregnancy. Hosp Med. 2000;61:93–96
  80. Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol. 1998;179:985–988
  81. von Kaisenberg CS, Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001;18:280–288
  82. Schild RL, Bald R, Plath H, et al. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 1999;13:161–166
  83. Smoleniec JS, Pillai M. Management of fetal hydrops associated with parvovirus B19 infection. Br J Obstet Gynaecol. 1994;101:1079–1081
  84. Forestier F, Tissot JD, Vial Y, Daffos F, Hohlfeld P. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Haematol. 1999;104:925–927
  85. Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345(8950):660–661
  86. Matsuda H, Sakaguchi K, Shibasaki T, et al. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med. 2005;33:561–563
  87. Gigler A, Dorsch S, Hemauer A, et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol. 1999;73:1974–1979
  88. Cohen BJ, Kumar S. Parvovirus B19 infection in pregnancy. Fetal Matern Med Rev. 2005;16:123–150
  89. Nagel HT, de Haan TR, Vandenbussche FP, Oepkes D, Walther FJ. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol. 2007;109:42–47

PII: S1744-165X(09)00008-0

doi: 10.1016/j.siny.2009.01.007

Seminars in Fetal & Neonatal Medicine
Volume 14, Issue 4 , Pages 218-221 , August 2009

Article Tools